This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kelly, F. J. Articles by Curiel, D. T. Search for Related Content PubMed PubMed Citation Articles by Kelly, F. J. Articles by Curiel, D. T.

Selectivity of TAG-72-targeted Adenovirus Gene Transfer to Primary Ovarian Carcinoma Cells versus Autologous Mesothelial Cells in Vitro¹

Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and Gene Therapy Center [C. R. M., J. G-N. D. T. C.], Division of Gynecologic Oncology, Department of Obstetrics/Gynecology [F. J. K., M. N. B., R. D. A.], Division of Radiation Biology, Department of Radiation Oncology [C. R. M., D. J. B.], and Department of Surgery, Division of Neurosurgery [C. R. M.], University of Alabama at Birmingham, Birmingham, Alabama 35294

ABSTRACT

Efficient gene transfer by recombinant adenovirus (Ad) vectors depends on expression of CAR and _v integrin on target cells. Because Ad may also infect nearby nontarget cells expressing these receptors, such as peritoneal mesothelial cells after i.p. injection, we hypothesized that targeting Ad gene delivery to a receptor overexpressed on most ovarian carcinoma cells, such as TAG-72, would enhance the selectivity of Ad gene transfer when used in this context. A monoclonal antibody that has been investigated clinically for immunotherapy and immunodetection of ovarian carcinomas, namely CC49, was used to construct a bispecific conjugate with the Fab fragment of a neutralizing anti-knob mAb to target Ad binding via TAG-72. This conjugate facilitated TAG-72-specific, CAR-independent Ad reporter gene transfer to both ovarian cancer cell lines and primary ovarian cancer cells cultured from malignant ascites fluid. Fab-CC49 was very selective for tumor cells, augmenting Ad gene transfer to primary ovarian cancer cells 2- to 28-fold relative to untargeted Ad, while also decreasing gene transfer to autologous cultured mesothelial cells 4- to 9-fold. These data suggest that targeting Ad via TAG-72 may improve the selectivity of Ad gene transfer for ovarian tumors 8- to 252-fold on i.p. vector injection. These results also define the requirements for a candidate target receptor in the rational design of a targeted Ad vector for ultimate clinical utility, one that selectively infects tumor cells and spares normal cells on i.p. injection. Such a vector may increase gene transfer and decrease the toxicity of Ad vectors, which would improve the therapeutic index of cytotoxic gene therapy for ovarian cancer in clinical trials.

This article has been cited by other articles:

				H.-J. Li, M. Everts, L. Pereboeva, S. Komarova, A. Idan, D. T. Curiel, and H. R. Herschman Adenovirus Tumor Targeting and Hepatic Untargeting by a Coxsackie/Adenovirus Receptor Ectodomain Anti-Carcinoembryonic Antigen Bispecific Adapter Cancer Res., June 1, 2007; 67(11): 5354 - 5361. [Abstract] [Full Text] [PDF]

				Y. Tsuruta, L. Pereboeva, J. N. Glasgow, D. T. Rein, Y. Kawakami, R. D. Alvarez, R. P. Rocconi, G. P. Siegal, P. Dent, P. B. Fisher, et al. A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus {sigma}1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor Independent Pathway Clin. Cancer Res., May 1, 2007; 13(9): 2777 - 2783. [Abstract] [Full Text] [PDF]

				H. C.A. Graat, P. I.J.M. Wuisman, V. W. van Beusechem, J. E. Carette, W. R. Gerritsen, J. Bras, G. R. Schaap, G. J.L. Kaspers, A. Ogose, W. Gu, et al. Coxsackievirus and Adenovirus Receptor Expression on Primary Osteosarcoma Specimens and Implications for Gene Therapy with Recombinant Adenoviruses Clin. Cancer Res., March 15, 2005; 11(6): 2445 - 2448. [Full Text] [PDF]

				Y. Wang, S. Thorne, J. Hannock, J. Francis, T. Au, T. Reid, N. Lemoine, D. Kirn, and G. Hallden A Novel Assay to Assess Primary Human Cancer Infectibility by Replication-Selective Oncolytic Adenoviruses Clin. Cancer Res., January 1, 2005; 11(1): 351 - 360. [Abstract] [Full Text] [PDF]

				K.-W. Peng, C. J. TenEyck, E. Galanis, K. R. Kalli, L. C. Hartmann, and S. J. Russell Intraperitoneal Therapy of Ovarian Cancer Using an Engineered Measles Virus Cancer Res., August 15, 2002; 62(16): 4656 - 4662. [Abstract] [Full Text] [PDF]

				W. Russell Adenovirus Gene Therapy for Ovarian Cancer J Natl Cancer Inst, May 15, 2002; 94(10): 706 - 707. [Full Text] [PDF]

				A. Hemminki, K. R. Zinn, B. Liu, T. R. Chaudhuri, R. A. Desmond, B. E. Rogers, M. N. Barnes, R. D. Alvarez, and D. T. Curiel In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus J Natl Cancer Inst, May 15, 2002; 94(10): 741 - 749. [Abstract] [Full Text] [PDF]

				G. J. Bauerschmitz, J. T. Lam, A. Kanerva, K. Suzuki, D. M. Nettelbeck, I. Dmitriev, V. Krasnykh, G. V. Mikheeva, M. N. Barnes, R. D. Alvarez, et al. Treatment of Ovarian Cancer with a Tropism Modified Oncolytic Adenovirus Cancer Res., March 1, 2002; 62(5): 1266 - 1270. [Abstract] [Full Text] [PDF]

				A. Kanerva, G. V. Mikheeva, V. Krasnykh, C. J. Coolidge, J. T. Lam, P. J. Mahasreshti, S. D. Barker, M. Straughn, M. N. Barnes, R. D. Alvarez, et al. Targeting Adenovirus to the Serotype 3 Receptor Increases Gene Transfer Efficiency to Ovarian Cancer Cells Clin. Cancer Res., January 1, 2002; 8(1): 275 - 280. [Abstract] [Full Text] [PDF]

				A. Hemminki, I. Dmitriev, B. Liu, R. A. Desmond, R. Alemany, and D. T. Curiel Targeting Oncolytic Adenoviral Agents to the Epidermal Growth Factor Pathway with a Secretory Fusion Molecule Cancer Res., September 1, 2001; 61(17): 6377 - 6381. [Abstract] [Full Text] [PDF]